Dezor (topical Ketoconazole) is generally used to help manage fungal and yeast-related skin conditions, providing symptomatic support across therapeutic domains involving localized discomfort. This medication is relevant for easing the symptom load associated with common infections like athlete's foot, jock itch, ringworm, and for conditions with recurrent manifestations, such as dandruff and seborrheic dermatitis. It is considered relevant in conditions involving episodic or fluctuating manifestations, such as Tinea versicolor.

---

“The treatment is applied when appropriate for conditions that present with disruptive symptom manifestations, providing supportive relief that assists with maintaining a normal appearance.”

This topical preparation helps address symptom clusters that may become intense or disruptive, including itching, burning, visible redness, and flaking. It contributes to improved comfort during symptomatic periods and may help support greater functional stability when these symptoms are more noticeable.

---

Quick Fact: Relief for Fungal Discomfort
Primary Goal: Supports easing the overall symptom load in conditions where physical discomfort and visible skin changes are prominent features.
Typical Scenario: Relevant in contexts involving heightened systemic burden, such as when symptoms become more noticeable during a flare-up of Tinea pedis or seborrheic scaling.

The official eligibility and non-eligibility profile for Dezor is determined by the specific formulation (e.g., oral, topical) and the formal statements made by major governmental regulatory bodies (such as the FDA, EMA, or other national health authorities). Currently, comprehensive official documentation for a product named "Dezor" that defines a universal eligibility map for all formulations is limited or not widely published.

However, regulatory documents for formulations containing ketoconazole (the active substance in some Dezor products) consistently define the following populations who must not use the medicine (Contraindications) or who require special consideration:

---

Official Eligibility Restrictions (Based on the Active Substance)

Eligibility Group	Restriction/Classification (Oral Formulation)
Allergy/Hypersensitivity	Contraindicated in individuals with known hypersensitivity to the active substance or any excipients.
Liver Disease	Contraindicated in patients with acute or chronic liver disease due to the risk of severe hepatotoxicity.
Age (Pediatric)	Use is generally not established or is restricted in children younger than a specified age (e.g., under 2 years for some topical forms).
Physiological State	Use in pregnancy and lactation is generally not recommended unless the benefits clearly outweigh the potential risks, and some official labels advise against use while breastfeeding.

---

Populations for whom use is allowed are typically adults who do not possess any of the documented contraindications and for whom the medicine has been officially prescribed. The existence of a contraindication legally prohibits the use of the medicine, thus structuring the final eligibility boundaries.

Interactions with other medicines and products

Dezor, a topical formulation containing Ketoconazole, has a minimal official interaction profile due to its negligible systemic absorption. Regulatory documents note that no formal drug interaction studies have been performed for the cream or shampoo, as plasma concentrations of Ketoconazole are typically not detectable in the bloodstream following topical use. This absence of systemic exposure eliminates the high risk of drug–drug interactions, such as those mediated by CYP450 enzymes, which are known to occur with the oral form of Ketoconazole.

Documented Interaction Constraints

The interaction profile is primarily defined by a procedural constraint involving co-administration with other topical agents:

Interacting Substance	Official Regulatory Statement
Systemic Medicines	No systemic pharmacokinetic interactions are documented. No specific systemic drugs are listed for co-administration restrictions.
Topical Corticosteroids	Requires a timing-based separation rule to prevent a potential rebound effect upon cessation of the steroid.
Food, Alcohol, Herbal Products	No known risks or restrictions are documented for co-administration.

Timing-Based Administration Rule

For patients transitioning from prolonged use of topical corticosteroids, official prescribing information mandates a specific timing separation: the topical corticosteroid should be applied in the morning, and Dezor should be applied in the evening. This procedure is required to manage the potential pharmacodynamic interaction related to skin response.

Dezor: Mechanism of Action (Pharmacodynamics)

Dezor (Ketoconazole) acts primarily as an inhibitor of the fungal enzyme, lanosterol 14-alpha-demethylase (CYP51), which is required for the synthesis of ergosterol. This molecular interference blocks a crucial step in the ergosterol pathway, leading to a severe ergosterol deficiency in the fungal cell membrane. The inhibition also causes the simultaneous buildup of toxic sterol precursors.

This cascade results in altered membrane integrity, compromising the cell's structural fluidity and permeability. The resulting failure of cellular homeostasis causes impaired nutrient transport and enzyme function, ultimately leading to the arrest of fungal growth and cell division (a fungistatic effect).

At higher, systemic concentrations, Dezor exhibits mechanistic cross-reactivity by inhibiting the human enzyme Steroid 17-alpha-hydroxylase (CYP17A1) in the host's steroidogenesis pathway. This action causes alterations in endogenous cortisol and sex steroid hormone levels.

Dezor, which contains the active ingredient Ketoconazole, is intended for topical, external application on the skin and scalp. The administration protocol involves applying a thin layer of the cream, gel, or foam formulation to the affected area and a small rim of the surrounding healthy skin.

Administration Regimens and Frequency

The specific dosing schedule is determined by the formulation and application site. For skin conditions like Tinea infections or cutaneous candidiasis, the standard frequency is typically once daily (q.d.). In contrast, treating seborrheic dermatitis typically involves application twice daily (b.i.d.) when using the cream or foam. The 2% shampoo formulation is initiated at a frequency of twice weekly for the treatment phase of scalp conditions.

Procedural Constraints and Duration

The duration of use is time-bound, typically ranging from two to four weeks for most initial treatment courses. Tinea Pedis (athlete’s foot) often requires a longer period, up to six weeks, to achieve the full effect. Specific procedural constraints exist for different forms: when using the foam formulation, it is dispensed onto a cool surface or the cap—not directly onto warm hands—to prevent melting. Furthermore, the shampoo requires a contact time of five minutes on the skin or scalp before rinsing when used for Pityriasis Versicolor. Following the initial clearance of a chronic condition, instructions for the shampoo may include a transition to intermittent application (e.g., once every one to two weeks) as a maintenance strategy. No specific dose adjustment is required for older adults, but use in children under 12 is generally not established.

Research evidence / Overview of studies for Dezor

Evidence for use in Seborrheic Dermatitis and Dandruff

Research exploring Dezor (topical Ketoconazole) for seborrheic dermatitis and dandruff has been primarily conducted through Randomized Controlled Trials (RCTs). These studies were applied in trials examining patient-reported experiences of physical discomfort, such as itching (pruritus), and visible signs, including scaling and redness (erythema). The populations in these trials were mainly adults with moderate to severe conditions, though some studies included adolescents. Studies reported measurements of changes in scaling and itching scores over the course of the typically short treatment periods. Reported patterns included measurements of fungal load (e.g., Malassezia species) at follow-up. Research explored short-term symptom changes, but since seborrheic dermatitis is a condition characterized by fluctuating or episodic manifestations, long-term outcomes and the durability of the initial reported outcome are not fully established.

Evidence for use in Pityriasis Versicolor (Tinea Versicolor)

Dezor was studied for its use in pityriasis versicolor through various clinical trials and systematic reviews. Research primarily examined two main outcomes: the mycological status (whether the fungus was observed) and the visual appearance of the skin lesions. In research exploring short-term symptom changes, findings describe patterns observed in the studies, including measurements of mycological status and the appearance of the affected areas. Follow-up periods were often included in the research to track the rate of recurrence. The evidence highlights what is known about the initial response, but the long-term effects are not fully established regarding the persistent outcome of the condition. Reported findings described various recurrence patterns and rates observed over time.

What is Still Uncertain About the Research

While the evidence base is structured around core clinical trials, several research limitations exist. Follow-up durations were limited across many key studies, meaning the long-term effects are not fully established, particularly for conditions prone to relapse. Comparative evidence is lacking in some areas, making it difficult to fully contextualize the findings against all available therapeutic options. Additionally, data for certain groups remain insufficient, with limited evidence available for older adults, children under the age of 12, or patients with certain comorbid conditions.

Common questions about Dezor (FAQ)

---

Q: How quickly does Dezor typically start to show its effects?

According to regulatory data from clinical trials, improvement in symptoms such as mycological clearing may begin within the first few days of application. However, full treatment courses, which aim to address the condition, typically range from two to six weeks, depending on the condition being addressed. Full restoration of skin appearance, such as normal pigmentation, may take several months.

Q: How does Dezor interact with common over-the-counter pain relievers?

Official product information indicates there are no known systemic interactions with other medicines, including over-the-counter pain relievers. This is because the topical formulation is designed for localized use and is minimally absorbed into the bloodstream.

Q: Do older adults (seniors) need to take any special precautions with Dezor?

Regulatory documents state that specific dose adjustments are not required for older adults when using the topical product. Use in this population is described as consistent with general instructions. The available evidence, however, is often noted as limited for both older adults and certain pediatric groups.

Q: Are there any specific times of day that Dezor is generally recommended to be taken?

The official documentation describes use as typically once or twice daily, depending on the specific skin condition and formulation used. The prescribing information only mandates a specific time-of-day separation rule when Dezor is co-administered alongside a topical corticosteroid medicine.

Q: What is the average duration of action for Dezor after taking it?

Studies examining the drug’s behavior indicate that the active ingredient remains concentrated in the outer layer of the skin, known as the stratum corneum, for at least 16 to 24 hours after application. Systemic plasma concentrations in the bloodstream are generally below detectable limits following standard topical use.

Q: Is Dezor considered a controlled substance?

According to regulatory classifications, the topical formulation of Dezor is not scheduled as a controlled substance under the Controlled Substances Act.

Q: Do topical side effects like fatigue, stomach upset, or weight changes occur?

The official adverse reaction documents for the topical product primarily list localized reactions, such as irritation or burning, at the application site. Systemic effects like fatigue, stomach upset, or weight changes are known to be associated with the oral form, but due to minimal absorption, they are not expected or reported with the topical formulation.

Q: Can Dezor affect birth control pills?

Authoritative patient information indicates that due to the localized application and lack of significant systemic absorption, the cream or shampoo forms of Dezor are not expected to affect the effectiveness of hormonal contraceptives like birth control pills.

Q: What should I do if I miss a dose of Dezor (general instructions only)?

General patient instructions for topical medicines advise that if a dose is missed, it should be applied as soon as the patient remembers. General guidance advises against using two doses at the same time or applying extra medication to make up for a missed application.

Q: Can Dezor cause dry mouth?

Dry mouth is an uncommon side effect listed in regulatory documents for the oral form of the active ingredient. Since the topical product is minimally absorbed into the body’s system, this reaction is not typically reported or expected with the use of Dezor.

Q: Is it necessary to have routine blood work done while taking Dezor?

Regulatory bodies have explicitly noted that the severe systemic effects associated with the oral form—which require routine monitoring of liver or adrenal function—have not been observed with the topical route. Therefore, routine blood work is not generally necessary based on the topical formulation's safety profile.

Q: Are there any known issues with driving or operating machinery while on Dezor?

Authoritative patient resources indicate that using the cream or shampoo formulations of Dezor is not known to affect a person’s ability to drive or operate machinery.

Q: Is Dezor available as a generic version?

Yes, the active ingredient in Dezor, Ketoconazole, is available in generic versions for the topical cream, gel, and shampoo formulations. These lower-cost alternatives contain the same active medicinal substance.

Q: What is the purpose of the 'black box warning' for Dezor, if any is present?

The Boxed Warning, or 'black box warning,' for potentially fatal liver injury and serious drug interactions is a regulatory caution that applies exclusively to the oral tablet form of the active ingredient. Topical formulations like Dezor have not been associated with these systemic problems.

Q: Is Dezor a prescription-only medicine?

The regulatory status of Dezor depends on the strength and formulation. The 2% cream, gel, and foam are typically available by prescription only. However, the lower-strength 1% shampoo is often available over-the-counter (OTC).

Q: Is there a patient information leaflet (PIL) available for Dezor?

Regulatory requirements for certain strengths mandate that the product package includes a Patient Information Leaflet (PIL) or a Medication Guide. This provides essential safety and usage details to the user.

Dezor's official storage and disposal requirements are dictated by regulatory labeling to maintain stability and ensure safety.

Official Storage Conditions

Requirement	Rule
Temperature	Cream must be stored at Controlled Room Temperature (20 C to 25 C). Shampoo must not be stored above 25 C.
Protection	The shampoo formulation requires protection from light. Flammable forms (gel/foam) must be stored away from heat or open flame.
Packaging	The product must be kept in the original, tightly closed container.
Safety	It is mandatory to Keep out of the sight and reach of children.

Disposal Requirements

Official instructions require unused or expired Dezor to be discarded according to local regulations or taken to an approved waste disposal site. Due to the active ingredient's environmental classification, disposal must avoid release into wastewater or household trash.